Accession Number
DB00479  (APRD00550)
Small Molecule
Approved, Investigational, Vet approved

Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.Label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.2

Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum)4. M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.4

Several forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection.6 In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.4,5

  • 1-N-(L(−)-γ-amino-α-hydroxybutyryl)kanamycin A
  • Amikacin
  • Amikacina
  • Amikacine
  • Amikacinum
External IDs
BAY 41-6551
Product Ingredients
IngredientUNIICASInChI Key
Amikacin sulfateN6M33094FD39831-55-5FXKSEJFHKVNEFI-GCZBSULCSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amikacin Sulfate InjectionSolutionIntramuscular; IntravenousOmega Laboratories Ltd2019-07-31Not applicableCanada
Amikacin Sulfate Injection USPSolutionIntramuscular; IntravenousMarcan Pharmaceuticals Inc2019-03-01Not applicableCanada
Amikacin Sulfate Injection USPLiquidIntramuscular; IntravenousSandoz Canada Incorporated2001-01-29Not applicableCanada
Amikacin Sulfate Injection, 500 mg/2mlInjection500 mg/1IntramuscularProdigy Innovation, LLC.2019-02-07Not applicableUs
AmikinSolution250 mgIntramuscular; IntravenousBristol Myers Squibb1977-12-312006-05-29Canada
ArikayceSuspension590 mg/8.4mLRespiratory (inhalation)Insmed Incorporated2018-10-12Not applicableUs
Erfa-amikacinSolutionIntramuscular; IntravenousErfa Canada 2012 Inc2019-11-29Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amikacin SulfateInjection250 mg/1mLIntramuscular; IntravenousWest-Ward Pharmaceuticals Corp.2015-08-01Not applicableUs
Amikacin SulfateInjection, solution50 mg/1mLIntramuscular; IntravenousFresenius Kabi USA, LLC2015-12-092015-12-14Us
Amikacin SulfateInjection, solution250 mg/1mLIntramuscular; IntravenousSagent Pharmaceuticals2016-06-15Not applicableUs
AMIKACIN SulfateInjection, solution1 g/4mLIntramuscular; IntravenousHospira, Inc.2005-09-302010-10-01Us
AMIKACIN SulfateInjection, solution500 mg/2mLIntramuscular; IntravenousHospira, Inc.2005-09-122012-11-01Us
AMIKACIN SulfateInjection, solution100 mg/2mLIntramuscular; IntravenousHospira, Inc.2005-02-282010-10-01Us
Amikacin SulfateInjection, solution250 mg/1mLIntramuscular; IntravenousBedford Pharmaceuticals1997-06-102010-03-31Us
Amikacin SulfateInjection, solution50 mg/1mLIntramuscular; IntravenousBedford Pharmaceuticals1997-07-102009-12-31Us
Amikacin SulfateInjection, solution1 g/4mLIntramuscular; IntravenousTeva Parenteral Medicines, Inc.1993-10-01Not applicableUs
Amikacin SulfateInjection, solution250 mg/1mLIntramuscular; IntravenousBedford Pharmaceuticals1994-05-312015-06-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Amexel (Abbott) / Amukin (Bristol-Myers Squibb) / Biklin (Bristol-Myers Squibb) / Erkacin (Brown & Burk) / Farcyclin (Faran Laboratories) / Flexelite (Bros) / Kamin (Bosch) / Novamin (Bristol-Myers Squibb) / Selaxa (Proel) / Selemycin (Medochemie) / Sikacin (Shiteh Organic) / Tipkin (T P Drug) / Tybikin (M & H) / Ukaject (Unimed Pharm) / Unikin (Union) / Uzix (Rafarm) / Xylanal (Epsilon)
CAS number
Average: 585.6025
Monoisotopic: 585.285736487
Chemical Formula
InChI Key



The amikacin sulfate injection is indicated in the short-term treatment of serious bacterial infections due to susceptible strains of gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, as well as Acinetobacter (Mima-Herellea) species.8

Clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery).8

Clinical studies have shown amikacin also to be effective in serious, complicated, and recurrent urinary tract infections due to the above organisms. Aminoglycosides, including amikacin, are not indicated in uncomplicated first-time episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxic.8

In September 2018, a new indication with a new dosage route was approved for this drug. Amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease).3 This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6 of treatment. Clinical benefit has not yet been established.Label

Important notes regarding Staphylococcus and Sensitivity testing:

Staphylococcus aureus, including methicillin-resistant strains, is the principal Gram-positive organism sensitive to amikacin. The use of amikacin in the treatment of staphylococcal infections should be restricted only to second-line therapy, and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibiotics.6

Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be used as initial therapy in suspected gram-negative infections and therapy may be initiated before obtaining the results of susceptibility testing.Label,6,8

Associated Conditions

Amikacin is an aminoglycoside antibiotic. Aminoglycosides bind to the bacteria, causing misreading of t-RNA, leaving bacteria unable to synthesize proteins vital to their growth. Aminoglycosides are useful mainly in the treatment infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, however, other antibiotics may be more potent and less toxic to humans.Label,6

Mechanism of action

The primary mechanism of action of amikacin is the same as that for all aminoglycosides. It binds to bacterial 30S ribosomal subunits and interferes with mRNA binding and tRNA acceptor sites, interfering with bacterial growth. This leads to disruption of normal protein synthesis and production of non-functional or toxic peptides. Other actions have been postulated for drugs of this class.Label,6,7 Amikacin, as well as the rest of the aminoglycosides, are generally bacteriocidal against gram-positive and gram-negative bacteria.4,8

A30S ribosomal protein S12
Escherichia coli (strain K12)
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Rapidly absorbed after intramuscular administration. Rapid absorption occurs from the peritoneum and pleura. Poor oral and topical absorption. Poorly absorbed from bladder irrigations and intrathecal administration.8,Label

The bioavailability of this drug is expected to vary primarily from individual differences in nebulizer efficiency and airway pathology.Label

Following IM administration of a single dose of amikacin of 7.5 mg/kg in adults with normal renal function, peak plasma amikacin concentrations of 17-25 micrograms/mL are attained within 45 minutes to 2 hours.6

Following IV infusion of the same dose given over 1 hour peak plasma concentrations of the drug average 38 micrograms/mL immediately following the infusion, 5.5 micrograms/mL at 4 hours, and 1.3 micrograms/mL at 8 hours.6

Volume of distribution
  • 24 L (28% of body weight healthy adult subjects).8

Following administration of usual dosages of amikacin, amikacin has been found in bone, heart, gallbladder, and lung tissue. Amikacin is also distributed into bile, sputum, bronchial secretions, and interstitial, pleural, and synovial fluids.6

Protein binding

The protein binding of amikacin in serum is ≤ 10%.Label


Amikacin's structure has been altered to reduce the possible route of enzymatic deactivation, thus reducing bacterial resistance. Many strains of Gram-negative organisms resistant to gentamicin and tobramycin have shown to be sensitive to amikacin in vitro.6

Route of elimination

This drug is eliminated by the kidneys. In adults with normal renal function, 94-98% of a single IM or IV dose of amikacin is excreted unchanged by glomerular filtration in the kidney within 24 hours. Amikacin can be completely recovered within approximately 10-20 days in patients with normal, healthy renal function.6

In patients with impaired renal function, the clearance of amikacin is found to be decreased; the more severe the impairment, the slower the clearance. The interval between doses of amikacin should be adjusted according to the level of renal impairment. Endogenous creatinine clearance rate and serum creatinine which have a high correlation with serum half-life of amikacin, may be used as a guide for dosing.6

Half life

The plasma elimination half-life of amikacin is usually 2-3 hours in adults with normal renal function and is reported to range from 30-86 hours in adults with severe renal impairment.Label


The mean serum clearance rate is about 100 mL/min and the renal clearance rate is 94 mL/min in subjects with normal renal function.8


Oral (LD50): 6000 mg/kg (Mouse) MSDS. No antidote for toxicity is currently available. This drug is only 20% dialyzable; however, this is variable based on the type hemodialysis filter used.4


Mild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Amikacin accumulates in the proximal renal tubular cells. Tubular cell regeneration occurs despite continued drug exposure. Toxicity most commonly occurs several days following initiation of therapy. Amikacin may exacerbate pre-existing renal disease.Label


May cause irreversible ototoxicity.Label Ototoxicity appears to be correlated to cumulative exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High- frequency hearing is lost first with progression leading to loss of low-frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness, and loss of balance.6,Label

Neuromuscular blockade

In addition to the above, amikacin may exacerbate neuromuscular blockade, however, this is less common.Label,4

Use in Pregnancy

Category D. Gentamicin and other aminoglycosides are known to cross the placenta. There is evidence of selective uptake of gentamicin by the fetal kidney resulting in damage to immature nephrons. Eighth cranial nerve damage has also been reported after in-utero exposure to some of the aminoglycosides. Because of the chemical similarity, all aminoglycosides should be considered potentially nephrotoxic and ototoxic to the developing fetus. Therapeutic blood amikacin levels in the mother do not equate with safety for the fetus. In reproductive toxicity studies in mice and rats, no effects on fertility or fetal toxicity were observed.6

Use in Lactation

It is not known whether amikacin is excreted in breast milk. Since the possible harmful effect on the infant is not known, it is recommended that if nursing mothers must be given amikacin, the infants should not be breastfed during therapy.6

Affected organisms
  • Humans and other mammals
  • Enteric bacteria and other eubacteria
Amikacin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
(R)-warfarinThe risk or severity of bleeding can be increased when Amikacin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Amikacin is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Amikacin is combined with 4-hydroxycoumarin.
AbacavirAmikacin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseAmikacin may decrease the excretion rate of Acarbose which could result in a higher serum level.
AceclofenacThe risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Amikacin.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Acemetacin is combined with Amikacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Amikacin is combined with Acenocoumarol.
AcetaminophenAmikacin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
AcetylcholineThe therapeutic efficacy of Acetylcholine can be decreased when used in combination with Amikacin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.


Synthesis Reference

Alberto Mangia, Vicenzo Giobbio, Giorgio Ornato, "Novel process for the synthesis of amikacin." U.S. Patent US4902790, issued August, 1984.

General References
  1. Edson RS, Terrell CL: The aminoglycosides. Mayo Clin Proc. 1999 May;74(5):519-28. [PubMed:10319086]
  2. Ramirez MS, Tolmasky ME: Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules. 2017 Dec 19;22(12). pii: molecules22122267. doi: 10.3390/molecules22122267. [PubMed:29257114]
  3. FDA Approves Arikayce [Link]
  4. Stat Pearls: Amikacin [Link]
  5. FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation [Link]
  6. MedSafe NZ: Amikacin Injection [File]
  7. EMA Withdrawal document, Arikayce [File]
  8. Amikacin, DailyMed [File]
External Links
Human Metabolome Database
KEGG Compound
PubChem Compound
PubChem Substance
Therapeutic Targets Database
PDBe Ligand
RxList Drug Page Drug Page
ATC Codes
S01AA21 — AmikacinD06AX12 — AmikacinJ01GB06 — AmikacinJ01RA06 — Cefepime and amikacin
AHFS Codes
  • 08:12.02 — Aminoglycosides
PDB Entries
4p20 / 6cgd
FDA label
Download (3.36 MB)
Download (73.4 KB)

Clinical Trials

Clinical Trials
0Not Yet RecruitingPreventionChronic Obstructive Pulmonary Disease (COPD)1
0Unknown StatusPreventionHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1Not Yet RecruitingTreatmentTuberculosis Infection1
1, 2CompletedTreatmentCystic Fibrosis (CF)2
2CompletedTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentDentin Sensitivity1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare1
2CompletedTreatmentMycobacteria, Atypical / Mycobacterium Infections, Nontuberculous1
2CompletedTreatmentMycobacterium Infections, Nontuberculous1
2CompletedTreatmentPneumonia, Bacterial1
2RecruitingPreventionCancer, Bladder / Urinary Tract Infection / Urologic Surgical Procedures1
2TerminatedTreatmentPneumonia, Bacterial1
2WithdrawnTreatmentPneumonia, Bacterial1
2WithdrawnTreatmentPulmonary Non-tuberculous Mycobacterial Lung Disease1
2, 3CompletedTreatmentVentilator-associated Bacterial Pneumonia1
2, 3Not Yet RecruitingTreatmentPulmonary Disease Due to Mycobacteria (Diagnosis)1
2, 3Unknown StatusTreatmentVentilator-associated Bacterial Pneumonia1
3CompletedTreatmentCystic Fibrosis (CF)1
3CompletedTreatmentMycobacterium Infections, Nontuberculous1
3CompletedTreatmentNTM Lung Infection Due to MAC1
3CompletedTreatmentNosocomial Neonatal Sepsis1
3CompletedTreatmentPneumonia, Bacterial2
3CompletedTreatmentPseudomonas Aeruginosa Infection1
3RecruitingPreventionVentilator-associated Bacterial Pneumonia / Ventilator-Associated Pneumonia (VAP)1
3WithdrawnTreatmentCystic Fibrosis (CF)1
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentInfection / Pneumonia1
4CompletedTreatmentNon-Cystic Fibrosis Bronchiectasis1
4Not Yet RecruitingTreatmentBurn Patients1
4Not Yet RecruitingTreatmentElderly Infection / Urinary Tract Infection1
4WithdrawnTreatmentGram Negative Meningitis / Post Traumatic Bacterial Meningitis1
Not AvailableCompletedNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiety / Anxiolysis / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Bradycardia / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest (CA) / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Chronic Kidney Disease (CKD) / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infection / Convulsions / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Dysrhythmia, Cardiac / Early-onset Schizophrenia Spectrum Disorders / Edema / Endocarditis / Epilepsies / Fibrinolytic Bleeding / Flu caused by Influenza / Gastroparesis / Gram-negative Infection / Gynaecological infection / Headache / Heart Failure / Heavy Menstrual Bleeding / Hemophilia / Herpes Simplex Virus / High Blood Pressure (Hypertension) / High Cholesterol / Hyperaldosteronism / Hyperlipidemias / Hypokalemia / Hypotension / Infantile Hemangiomas / Infection / Infection caused by staphylococci / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Insomnia / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Methicillin Resistant Staphylococcus Aureus (MRSA) / Migraine / Muscle Spasms / Nausea / Neuromuscular Blockade / Neutropenia / Nosocomial Pneumonia / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Pulmonary Arterial Hypertension (PAH) / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenia / Sedation / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and skin-structure infections / Skin and Subcutaneous Tissue Bacterial Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombotic events / Toxic effect of hydrocyanic acid and cyanides / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infection / Vomiting / Withdrawal1
Not AvailableCompletedPreventionNeonatal Sepsis1
Not AvailableCompletedTreatmentAsthma / Chronic Lung Diseases / Chronic Obstructive Pulmonary Disease (COPD) / Cystic Fibrosis (CF) / Respiratory Diseases1
Not AvailableCompletedTreatmentChronic Bronchitis / Cystic Fibrosis (CF)1
Not AvailableCompletedTreatmentCystic Fibrosis (CF)1
Not AvailableCompletedTreatmentFevers / Malignancies / Neutropenia1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentVentilator-associated Bacterial Pneumonia / Ventilator-Associated Pneumonia (VAP)1
Not AvailableCompletedTreatmentVentilator-associated Bacterial Pneumonia1
Not AvailableNot Yet RecruitingTreatmentSepsis / Shock, Septic / Systemic Inflammatory Response Syndrome (SIRS)1
Not AvailableRecruitingNot AvailableCerebral Hemorrhage / Subarachnoid Hemorrhage / Therapeutic Drug Monitoring1
Not AvailableRecruitingNot AvailableTuberculosis Infection1
Not AvailableRecruitingDiagnosticCystic Fibrosis (CF)1
Not AvailableRecruitingTreatmentAppendicitis / General Surgery1
Not AvailableRecruitingTreatmentChronic Skin Ulcers1
Not AvailableRecruitingTreatmentCystic Fibrosis (CF) / Healthy Volunteers1


  • Abbott laboratories
  • Abbott laboratories hosp products div
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Apothecon inc div bristol myers squibb
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bristol-Myers Squibb Co.
  • Hospira Inc.
  • Mead Johnson and Co.
  • Medisca Inc.
  • Sicor Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
InjectionIntramuscular; Intravenous250 mg/1mL
Injection, solutionIntramuscular; Intravenous1 g/4mL
Injection, solutionIntramuscular; Intravenous100 mg/2mL
Injection, solutionIntramuscular; Intravenous500 mg/2mL
LiquidIntramuscular; Intravenous
SolutionIntramuscular; Intravenous
InjectionIntramuscular500 mg/1
Injection, solutionIntramuscular; Intravenous250 mg/1mL
Injection, solutionIntramuscular; Intravenous50 mg/1mL
SolutionIntramuscular; Intravenous250 mg
SuspensionRespiratory (inhalation)590 mg/8.4mL
Unit descriptionCostUnit
Amikacin sulfate powder26.01USD g
Amikacin (pf) 500 mg/2 ml2.53USD ml
Amikacin 250 mg/ml vial2.19USD ml
Amikacin (pf) 100 mg/2 ml1.8USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
melting point (°C)214MSDS
boiling point (°C)632.23
water solubility50 mg/ml
logS-0.5ADME Research, USCD:
Predicted Properties
Water Solubility49.7 mg/mLALOGPS
pKa (Strongest Acidic)12.1ChemAxon
pKa (Strongest Basic)9.79ChemAxon
Physiological Charge4ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area331.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity129.84 m3·mol-1ChemAxon
Polarizability58.06 Å3ChemAxon
Number of Rings3ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Human Intestinal Absorption-0.9405
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7583
P-glycoprotein substrateSubstrate0.5129
P-glycoprotein inhibitor INon-inhibitor0.7336
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8614
CYP450 2C9 substrateNon-substrate0.816
CYP450 2D6 substrateNon-substrate0.8309
CYP450 3A4 substrateNon-substrate0.5664
CYP450 1A2 substrateNon-inhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.9237
CYP450 2D6 inhibitorNon-inhibitor0.9249
CYP450 2C19 inhibitorNon-inhibitor0.9128
CYP450 3A4 inhibitorNon-inhibitor0.9434
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8866
Ames testNon AMES toxic0.6813
BiodegradationNot ready biodegradable0.5512
Rat acute toxicity1.7506 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9926
hERG inhibition (predictor II)Non-inhibitor0.6366
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available


This compound belongs to the class of organic compounds known as 4,6-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C6-positions.
Organic compounds
Super Class
Organic oxygen compounds
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
4,6-disubstituted 2-deoxystreptamines
Alternative Parents
Gamma amino acids and derivatives / O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexanols / Cyclohexylamines / Oxanes / Monosaccharides / N-acyl amines / 1,3-aminoalcohols / 1,2-aminoalcohols
show 10 more
4,6-disubstituted 2-deoxystreptamine / Gamma amino acid or derivatives / Glycosyl compound / O-glycosyl compound / Aminocyclitol or derivatives / Cyclohexanol / Cyclohexylamine / Fatty acyl / Monosaccharide / N-acyl-amine
show 27 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
alpha-D-glucoside, aminoglycoside, carboxamide, amino cyclitol glycoside (CHEBI:2637)


Escherichia coli (strain K12)
Pharmacological action
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
Uniprot ID
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tolmasky ME: Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9. [PubMed:10702385]
  4. Amikacin, DailyMed [File]
  5. MedSafe NZ: Amikacin Injection [File]

Drug created on June 13, 2005 07:24 / Updated on April 03, 2020 10:24

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.